An international team of researchers has discovered a natural mechanism that protects the heart from heart failure with preserved ejection fraction (HFpEF), a serious condition in need of effective ...

Get Instant Summarized Text (Gist) A natural mechanism that protects against heart failure with preserved ejection fraction (HFpEF) has been identified. When this mechanism fails, it leads to ...

The results from the SUMMIT trial of tirzepatide in obese patients with heart failure with preserved ejection fraction (HFpEF) showed that Lilly's drug cut the risk of cardiovascular mortality and ...

Tenax Therapeutics progresses levosimendan for PH-HFpEF with Phase 3 trials, aiming for a first-of-its-kind therapy. Click ...

Finerenone prevented new-onset atrial fibrillation or flutter in patients with chronic kidney disease and type 2 diabetes or ...

An ejection fraction >35% is unconventional to be considered "preserved," so the results of this trial are inconclusive on whether patients with heart failure and ejection fractions usually ...

Eli Lilly's dual GLP-1/GIP agonist tirzepatide has been shown ... The SUMMIT trial enrolled obese patients with heart failure with preserved ejection fraction (HFpEF) – a particularly hard ...

Understanding how patients with heart failure with preserved ejection fraction (HFPEF) die provides insight into the natural history and pathophysiology of this complex syndrome, thereby allowing ...

Tirzepatide has also been shown to improve health status and lower the risk of death in people with obesity and heart failure with preserved ejection fraction. You don’t have control over all the ...

The growing morbidity, mortality, and health care costs related to heart failure (HF) underscore the urgent need to ...